Literature DB >> 17709888

The status of gene vectors for the treatment of diabetes.

John A Zaia1.   

Abstract

Diabetes mellitus type 1 (DM1) represents one of the most obvious targets for successful treatment by gene transfer. The disease provides targets and methods for therapy that include suppression of autoimmunity, restoration of insulin responsiveness, functional replacement of pancreatic islets, and correction of vascular and nerve damage associated with prolonged hyperglycemia. The pathogenesis of DM1 is well understood and gene sequences are known that would support these various approaches for genetic intervention. However, a key limitation at present is the availability of efficient and reliable methods for delivery and sustained expression of the transferred DNA. Most genetic vectors are derived from viruses, and recent improvements in adenovirus-derived, lentivirus-derived, and adeno-associated virus-derived vectors suggest that these will have successful application to diabetes in the future.

Entities:  

Mesh:

Year:  2007        PMID: 17709888     DOI: 10.1007/s12013-007-0023-8

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  4 in total

1.  Personalized medicine for diabetes.

Authors:  David C Klonoff
Journal:  J Diabetes Sci Technol       Date:  2008-05

2.  Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices.

Authors:  Michael-A van Geer; Koert F D Kuhlmann; Conny T Bakker; Fibo J W ten Kate; Ronald P J Oude Elferink; Piter J Bosma
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

3.  Gene therapy for type 1 diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin gene.

Authors:  Li Niu; Yan-Cheng Xu; Zhe Dai; Hui-Qin Tang
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

4.  Diabetes mellitus: new challenges and innovative therapies.

Authors:  Cristina M Sena; Carla F Bento; Paulo Pereira; Raquel Seiça
Journal:  EPMA J       Date:  2010-03-13       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.